Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)
- Sponsor
- Military University Hospital, Prague
- Study ID
- NCT07424963
- Status
- Recruiting
Conditions
- Cirrhosis
- EUS
- HVPG
- Hepatic Venous Pressure Gradient
- Non-Cirrhotic Portal Hypertension
- Portal Hypertension
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Hepatic venous pressure gradient measurement — PROCEDUREHVPG measurement is minimally invasive procedure that involves cannulation of the right internal jugular vein, followed by the insertion of a balloon-occlusion catheter into the right or middle hepatic vein to measure both free hepatic vein pressure and wedged hepatic vein pressure, enabling the calculation of HVPG. Additionally, this method allows for liver biopsy during the same session. HVPG is widely regarded as the gold standard for PPG measurement.
- Endoscopic ultrasound-guided portal pressure gradient measurement — PROCEDURERecent advancements in the field of digestive endoscopy have introduced an innovative alternative: endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement. This emerging technique shows promise for further improving the accessibility of portal hypertension assessment and also offers the possibility of liver biopsy in one session. EUS-PPG may have several advantages, including its minimally invasive nature, safety profile, high technical success rate, the possibility of a "one-stopshop" approach (combining EUS-PPG, liver biopsy, and endoscopic treatment of esophageal varices), absence of radiation exposure.
Study Details
The goal of this interventional trial is to compare in measuring of portal hypertension by HVPG and EUS-PPG in subject indicated to HVPG measurement. The primary question is whether EUS-PPG provides measurements really equivalent to HVPG in terms of gradient accuracy. Participants undergoing HVPG will first undergo the procedure while conscious, performed by the first operator. Immediately thereafter, HVPG will be repeated following the induction of anesthesia by a second operator blinded to the initial readings. Subsequently, EUS-PPG will be performed by an endoscopist, who will also be blinded to all previous pressure measurements.
Key Dates
- First listed
- Feb 20, 2026
- Start date
- May 30, 2025
- Status verified
- Jan 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: ParticipantsParticipants undergoing HVPG will first undergo the procedure while conscious, performed by the first operator. Immediately thereafter, HVPG will be repeated following the induction of anesthesia by a second operator blinded to the initial readings. Subsequently, EUS-PPG will be performed by an endoscopist, who will also be blinded to all previous pressure measurements.
Primary Outcome Measure
Evaluation of the consistency between the HVPG and EUS-PPG [ Time Frame: 30 days after enrollment ]
Central Contacts
- Petr Hříbek, MD, PhD+420973203065
- Petr Urbánek, Prof.
Related Studies
- Blood Collection Biorepository for Liver Disease ResearchRecruiting · State University of New York at Buffalo · Buffalo, New York
- Mechanisms of Malnutrition in Cirrhosis With Portosystemic ShuntingRecruiting · The Cleveland Clinic · Cleveland, Ohio
- Novel Tracer Methods to Evaluate Muscle Protein Metabolism in CirrhosisRecruiting · The Cleveland Clinic · Cleveland, Ohio
- Safety and Efficacy of Atorvastatin v. Placebo on HCC RiskPHASE2 · Recruiting · Raymond Chung · Boston, Massachusetts